Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTelo Genomics Corp

Telo Genomics Corp

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.05 CAD 0.00(0%)
Last update at 2026-11-03T14:30:00Z
Market Cap
5.02M

Momentum Score

…

Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with a high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM, which predicts newly diagnosed MM patients who may relapse on first-line therapy; TeloMRD-D, which identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD-detected cells in post-transplant patients. It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.05
Low
0.05
High
52 Week Price Range
0.04
Low
0.12
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Telo Genomics Corp (TSXV: TELO) is a small-cap company listed on the TSX Venture Exchange in the genomics/biotech sector. Long-term growth drivers for companies in this space include rising demand for molecular diagnostics, aging research, and wider adoption of precision medicine, which may benefit firms that achieve technical validation and scalable commercialization.
Key investment risks include limited public disclosures and short operating history, execution and regulatory uncertainty common to early-stage biotech, and likely financing needs that could dilute shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-4675.28%
Net Debt
-
ROCE
-524.75%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -2.72M -2.71M -2.82M -2.11M -1.07M
Net income -2.72M -2.71M -2.82M -2.11M -1.07M
Selling general administrative 1.31M 1.36M 1.46M 0.99M 0.65M
Gross profit - - -0.03M -0.06M -0.06M
Reconciled depreciation 0.01M 0.04M 0.03M 0.06M 0.06M
Ebit - - -2.82M -2.11M -1.07M
Ebitda - - -2.79M -2.05M -1.01M
Depreciation and amortization - - 0.03M 0.06M 0.06M
Operating income -2.70M -2.72M -2.82M -2.11M -1.07M
Other operating expenses - - 2.82M 2.11M 1.26M
Interest expense - - 0.01M 0.01M 0.00M
Net interest income - - - - 0.00M
Income tax expense - - -0.01M -0.01M 0.18M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 2.70M 2.72M 2.82M 2.11M 1.26M
Cost of revenue - - 0.03M 0.06M 0.06M
Total other income expense net -0.02M 0.01M -0.01M -0.01M 0.19M
Net income from continuing ops -2.72M -2.71M -2.82M -2.11M -1.07M
Net income applicable to common shares - - - -2.11M -1.07M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 0.91M 0.97M 2.93M 2.83M 3.84M
Total liab 0.40M 0.38M 0.31M 0.23M 0.15M
Total stockholder equity 0.51M 0.59M 2.61M 2.60M 3.69M
Common stock - - - 19.11M 18.23M
Capital stock 24.57M 22.35M 21.69M 19.11M 18.23M
Retained earnings -30.55M -27.83M -25.12M -22.30M -20.19M
Cash 0.79M 0.80M 2.67M 2.69M 3.64M
Total current liabilities 0.40M 0.38M 0.28M 0.19M 0.11M
Property plant equipment - - - 0.02M 0.06M
Total current assets 0.89M 0.92M 2.84M 2.79M 3.76M
Net tangible assets - - - 2.58M 3.61M
Net receivables 0.03M 0.03M 0.06M 0.04M 0.10M
Long term debt - - 0.03M 0.04M 0.04M
Accounts payable - - - 0.19M 0.10M
Non current assets total 0.02M 0.05M 0.08M 0.05M 0.08M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.00M -0.01M -0.07M -0.03M -0.01M
Change to liabilities - - - 0.08M -0.04M
Total cashflows from investing activities - - - -0.03M -0.01M
Net borrowings 0.00M - - - -0.01M
Total cash from financing activities 2.33M 0.59M 2.68M 0.88M 3.83M
Change to operating activities - - - -0.03M 0.04M
Net income -2.72M -2.71M -2.82M -2.11M -1.07M
Change in cash -0.01M -1.88M -0.02M -0.94M 2.72M
Begin period cash flow 0.80M 2.67M 2.69M 3.64M 0.92M
End period cash flow 0.79M 0.80M 2.67M 2.69M 3.64M
Total cash from operating activities -2.33M -2.46M -2.63M -1.79M -1.10M
Issuance of capital stock 2.55M 0.65M 2.83M 0.20M 2.09M
Depreciation 0.01M 0.04M 0.03M 0.06M 0.06M
Change to account receivables - - -0.03M 0.06M -0.05M
Other cashflows from financing activities - - -0.15M 0.68M 1.75M
Change to netincome - - - 0.15M -0.05M
Capital expenditures 0.00M 0.01M 0.07M 0.03M 0.01M
Change in working capital 0.04M 0.16M -0.00M 0.11M -0.05M
Stock based compensation 0.27M 0.06M 0.16M 0.15M 0.14M
Other non cash items 0.05M - 0.25M 0.21M -0.18M
Free cash flow -2.33M -2.46M -2.70M -1.82M -1.11M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
TELO
Telo Genomics Corp		 -
-%		 0.05 - - - 8.78 -6.32
AVCR
Avricore Health Inc		 -
-%		 0.05 - - 3.16 5.09 41.13
ARC
Arian Resources Corp.		 -
-%		 0.01 - - 2.12 - 2.25
MBI-H
Med BioGene Inc		 -0.01
25.00%		 0.01 - - - - -3.03

Profile*

Telo Genomics Corp

Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with a high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM, which predicts newly diagnosed MM patients who may relapse on first-line therapy; TeloMRD-D, which identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD-detected cells in post-transplant patients. It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.

555 Richmond Street West, Toronto, ON, Canada, M5V 3B1

647-477-9365

https://www.telodx.com

Name Title Year Born
Dr. Sherif Louis MSc, Ph.D., PMP CEO & Pres NA
Dr. Sabine Mai Ph.D. Founder, Member of Clinical & Scientific Advisory Board and Director NA
Mr. Christopher Ross CPA, CGA Chief Financial Officer NA
Dr. Sabine Mai Ph.D. Founder, Interim CEO, Chair of the Clinical & Scientific Advisory Board and Director NA
Dr. Sherif Louis MSc, Ph.D., PMP President & CTO NA
Mr. Guido Baechler Executive Chairman 1965
Dr. Hans Knecht M.D. Medical laboratory Director & Member of Clinical Advisory Board NA
Dr. Mark Stene M.B.A., Ph.D. Head of Laboratory Operations NA
Mr. John Prince Chief Financial Officer NA
Mr. John Allen Farlinger C.A. CEO & Chairman of the Board 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 29.99
+13.13%
AP-UN
CAD 4.19
+12.94%
ARTG
CAD 39.66
+12.93%
BZ
CAD 4.14
+10.99%
FFH
CAD 2759.48
+10.87%
DRUG
CAD 27.12
-26.86%
HUT
CAD 69.10
-22.27%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.85
-14.43%
MOON
CAD 4.09
-12.79%

Equity Sectors*

  • Basic Materials

    +3.69%

  • Communication Services

    +2.61%

  • Consumer Cyclical

    +2.96%

  • Consumer Defensive

    +1.11%

  • Energy

    -5.01%

  • Financial Services

    +2.20%

  • Healthcare

    -0.56%

  • Industrials

    -0.73%

  • Real Estate

    +1.90%

  • Technology

    +0.05%

  • Utilities

    +1.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…